Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 12;2(3):211-213.
doi: 10.1016/j.medj.2021.02.006.

Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies

Ramez N Eskander  1 , Razelle Kurzrock  2
Affiliations
Comment

Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies

Ramez N Eskander et al. Med. .

Abstract

Molecular tumor testing has transformed the treatment of patients with malignancies and is helping catalyze the development of novel therapeutic strategies. In a recent issue of The New England Journal of Medicine, Arakawa et al. describe two cases of pediatric lung cancer resulting from mother-to-infant transmission, diagnosed remote from delivery.1.

PubMed Disclaimer

Conflict of interest statement

DECLARATION OF INTERESTS Dr. Eskander receives research funding from Clovis Oncology, Merck, and AstraZenca, as well as consultant and/or speaker fees and/or advisory board from AstraZeneca, GSK/Tesaro, Myriad, Merck, and the GOG Foundation. Dr. Kurzrock receives research funding from Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq, and Guardant, as well as consultant and/or speaker fees and/or advisory board for X-Biotech, Neomed, Pfizer, Actuate Therapeutics, Roche, Turning Point Therapeutics, TD2/Volastra, Bicara Therapeutics, Inc.; has an equity interest in IDbyDNA and CureMatch Inc; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch.

Figures

Figure 1.
Figure 1.. Transmission of cervical cancer from mothers to infants
(A) Potential routes for cancer transmission by transplacental hematogenous dissemination or direct transmission at the time of delivery. (B) Next-generation sequencing of the pediatric lung tumors confirmed maternal transmission and led to personalized therapy (image credit: adapted form Servier Medical Art by Servier).
See this image and copyright information in PMC

Comment on

  • Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.
    Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T, Ogawa C. Arakawa A, et al. N Engl J Med. 2021 Jan 7;384(1):42-50. doi: 10.1056/NEJMoa2030391. N Engl J Med. 2021. PMID: 33406329

References

    1. Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, et al. (2021). Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.N. Engl. J. Med 384, 42–50. - PubMed
    1. Teksam M, McKinney A, Short J, Casey SO, and Truwit CL (2004). Intracranial metastasis via transplacental (vertical) transmission of maternal small cell lung cancer to fetus: CT and MRI findings. Acta Radiol. 45, 577–579. - PubMed
    1. Herskovic E, Ryan M, Weinstein J, and Wadhwani NR (2014). Maternal to fetal transmission of cervical carcinoma. Pediatr. Radiol 44, 1035–1038. - PubMed
    1. Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H,et al. (2019). Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 110, 1480–1490. - PMC - PubMed
    1. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, et al. (2017). Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390, 1654–1663. - PMC - PubMed

Publication types